Consumption of calcium antagonists: Results of the German National Health Surveys

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 3, 2000, Pages 221-233

  Knopf, Hildtraud ^a   Melchert, Hans Ulrich ^a   Bertelsmann, Annekarin ^b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b Fed Inst Drugs and Med Devices   (Germany)

Author keywords

Calcium antagonists; Clinical chemistry; Drug utilization; Hypertension; Indication; Multimedication; Representative population surveys; Side effects; Tolerability

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FELODIPINE; FENDILINE; GALLOPAMIL; ISRADIPINE; LIDOFLAZINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; NITRENDIPINE; PERHEXILINE MALEATE; VERAPAMIL;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL TOXICITY; GERMAN FEDERAL REPUBLIC; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUSCULOSKELETAL DISEASE; PERIPHERAL NEUROPATHY; PHARMACOEPIDEMIOLOGY; PHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SKIN TOXICITY; SOCIAL ASPECT; STATISTICS; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 0033924665     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1557(200005/06)9:3<221::AID-PDS499>3.0.CO;2-P     Document Type: Article

References (31)

1. Rang HP, Dale MM, Ritter JM, Gardner P (eds) Pharmacology. Churchill Livingstone Inc.: New York, Edinburgh, London, Melbourne, Tokyo, 1995.
2. Schroeder JS. Treatment of coronary artery spasm with calcium blockers - variant angina and unstable angina. In Calcium Blockers - Mechanisms of Action and Clinical Applications, Flaim SF, Zelis R (eds). Urban & Schwarzenberg: Baltimore, Munich, 1982; 219-231.
3. Scholz H. Calcium-Antagonisten. In Arzneiverordmmgsreport '97 (Hrsg: WIdO der AOK), Verfügungsbeklagte Ausgabe ohne Aufstellung umstrittener Arzneimittel, Schwabe U (ed.) Gustav Fischer Verlag: Stuttgart, Jena, 1997; 214-223.
4. Schwabe U, Paffrath D. Arzneiverordnungsreport '87-'98 (Hrsg: WldO der AOK). Gustav Fischer Verlag: Stuttgart, Jena, 1987-1998.
5. GCP-Study Group. The German Cardiovascular Prevention Study (GCP): Design and Methods. Eur Heart J 1988; 9: 1058-1066.
6. Hoffmeister H, Hüttner H, Stolzenberg H, Lopez H, Winkler J. (eds) Sozialer Status und Gesundheit, bga Schriften, Bd. 2. MMV Verlag: München, 1992.
7. Forschungsverbund DHP. (ed) Die Deutsche Herz-Kreislauf-Präventionsstudie. Verlag Hans Huber: Bern, Göttingen, Toronto, Seattle, 1998.
8. Bellach BM, Knopf H, Thefeld W. Der Bundes-Gesundheitssurvey 1997/98. Gesundheitswesen 1998 Dez; 60 Suppl 2: 59-68.
9. Hoffmeister H, Mensink GBM, Stolzenberg H. National trends in risk factors for cardiovascular diseases in Germany. Prevent Med 1994; 23: 197-205.
10. Güther B. Strukturdaten von Teilnehmergruppen in Gesundheitserhebungen. In DHP-Forum 1/86, WIAD (ed). WIAD Bonn, 1986: 61-77.
11. Thefeld W, Stolzenberg H, Bellach BM. Bundesgesundheitssurvey: Response, Zusammensetzung der Teilnehmer, Non-responder-analyse. Gesundheitswesen 1999; 6 Sonderheft 2: 57-61.
12. Melchert HU, Görsch B, Hoffmeister H. (eds) Zur Epidemiologie des Arzneimittelkonsums und der unerwünschten Arzneimittelwirkungen: Nichtstationäre Arzneimittelanwendung und subjektive Arzneimittelverträglichkeit in der bundesdeutschen Wohnbevölkerung der 25-bis 69jährigen -Ergebnisse der Erhebung des ersten Nationalen Untersuclnings-Surveys 1984-1986, RKI Schriften 1/95. MMV Verlag: München, 1995.
13. Chalmers J, MacMahon, Mancia G, et al. WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-185.
14. Bundesverband der Pharmazeutischen Industrie e.V. (ed) Pharma Daten '88-'96. Druckhaus Beltz: Hemsbach, 1988-1996.
15. Maggioni AP, Franzosi MG, Latini R. Calcium antagonists. In Side Effects of Drugs, Annual 22, Aronson JK (ed). Elsevier: Amsterdam, Lausanne, New York, Oxford, Shannon, Singapore, Tokyo, 1999; 214-220.
16. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long term survival and use of antihypertensive medications in older persons. J Am Geriat Soc 1995; 43: 1191-1197.
17. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
18. Koenig W, Loewel H, Lewis M, Hoermann A. Long-term survival after myocardial infarction: relationship with thrombosis and discharge medication. Results of the Augsburg myocardial infarction follow-up study 1985-1993. Eur Heart J 1996; 17: 1199-1206.
19. Josefson D. Infarction risk found with calcium channel blocker. BMJ 1998; 316: 797.
20. Pahor M, Guralnik JM, Ferrucci L et al. Calcium-channel blockade and the incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
21. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium channel blockers and risk of cancer. Lancet 1997; 349: 525-528.
22. Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
23. Ahr JH, Bomhard E, Enzmann H et al. Calcium channel blockers and the risk of cancer: a preclinical assessment. Cardiovasc Drugs Ther 1998; 12: 157-169.
24. Lindberg G, Bingefors K, Ranstam J, Rastam L, Melander A. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. BMJ 1998; 316: 741-745.
25. Hansen HJ, Fischer J. Is the safety and efficacy of calcium antagonists now established? Cardiovasc Drugs Ther 1998; 12: 145-147.
26. Bertelsmann A, Knopf H, Melchert HU. Der Bundes-Gesundheitssurvey als pharmakoepidemiologisches-Instrument. Gesundheitswesen 60, 1998; Sonderheft 2: 89-94.
27. Orme S, Da Costa D, Messenger A. Generalized pruritus associated with amlodipine. BMJ 1997; 315: 463.
28. Vincente Calleja JM, Aguirre A, Landa N, Crespo V, Gonzàlez-Perez R, Diaz-Perez R. Acute generalized exanthematous pustulosis due to diltiazem: confirming by patch testing. Br J Dermatol 1998; 137: 837-839.
29. Basarab T, Yu R, Russel Jones R. Calcium antagonist-induced photo-exposed telangiectasia. Br J Dermatol 1997; 136: 974-975.
30. Tsele E, Chu AC. Nifedipine and telangiectasias. Lancet 1992; 339: 365-366.
31. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992; 63: 453-456.